Premium
Genetic variation in the human α2B‐ADRENERGIC receptor gene: Haplotypes and yohimbine response
Author(s) -
Etzel J. P.,
Rana B. K.,
Wen G.,
Parmer R. J.,
Schork N. J.,
O'Connor D. T.,
Insel P. A.
Publication year - 2005
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1016/j.clpt.2004.11.028
Subject(s) - yohimbine , haplotype , single nucleotide polymorphism , genotype , medicine , pharmacogenetics , genotyping , snp , pharmacology , biology , receptor , antagonist , genetics , gene
Background/Aims An exaggerated increase in blood presssure by α2‐adrenergic receptor (α2‐AR) blockade produced by infusion of the antagonist yohimbine can predict increased risk for hypertension. We assessed α2‐AR's as candidate genes influencing baseline and yohimbine‐promoted increase in mean arterial pressure (MAP). Methods/Results Infusion of yohimbine and genotyping of 173 healthy individuals for common polymorphisms within the three α2‐AR subtypes identified a synonymous SNP in the α2B‐gene (ADRA2B) as a determinant of yohimbine response. Sequencing of ADRA2B in 254 individuals identified 2 major haplotypes that differ by the presence of a 9‐bp in‐frame deletion (Del Glu301–303). Del/Del homozygotes were less frequent in older subjects (13.6% and 2.3% in individuals